Navigating inflation penalties, public perception, and pharmaceutical revenue management. In 2015, Turing Pharmaceuticals CEO Martin Shkreli raised the price of Daraprim from $13.50 to $750 per pill, generating a wave of negative publicity and prompting the swift passage of Section 602 in the Bipartisan Budget Act of 2015 (BBA). This legislation imposes the same inflation…